Every Form 4 that Kailera Therapeutics, Inc. (KLRA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow KLRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KLRA filings page.
Kailera Therapeutics, Inc. (KLRA) reported that its Chief Technology Officer, Nicholson Nur, received a grant of stock options to acquire 220,000 shares of common stock on September 7, 2026 at an exercise price of $16.23 per share, expiring September 7, 2036.
The options vest as to 25% of the underlying shares on August 31, 2027 and thereafter in 36 substantially equal monthly installments, subject to Nur’s continued service through each vesting date. No Rule 10b5-1 trading plan is reported.
Kailera Therapeutics, Inc. reported that officer Kathleen Tregoning received a grant of stock options covering 175,000 shares of common stock. The options have an exercise price of $23.30 per share and expire on July 6, 2036.
These options vest as to 25% of the underlying shares on June 29, 2027 and then in 36 substantially equal monthly installments, subject to her continued service. Following this grant, she holds stock options exercisable for 175,000 shares directly.
Kailera Therapeutics, Inc. CEO and President Ronald C. Renaud Jr. exercised stock options to acquire 38,094 shares of common stock at an exercise price of $5.25 per share on June 9, 2026. Following the transaction, he directly holds 38,094 common shares.
The exercised options covered 38,094 underlying shares out of a larger grant, with 817,826 stock options reported as remaining after the transaction and expiring on September 19, 2034. The options began vesting on September 9, 2025 and continue vesting in substantially equal monthly installments, conditioned on his continued service.
RTW Investments-managed funds, as ten percent owners of Kailera Therapeutics, reported increasing their indirect position in the company. On April 20, 2026, affiliated funds bought 500,000 shares of Common Stock in open-market transactions at $16.00 per share.
On the same date, all held Series A and Series B Preferred Stock automatically converted into Common Stock on a 1-for-1 basis for no additional consideration immediately before the closing of the initial public offering, adding 10,276,820 shares. After these conversions and purchases, the affiliated funds indirectly held 10,776,820 shares of Common Stock. The filing notes that RTW and Roderick Wong disclaim beneficial ownership except to the extent of their pecuniary interest.
Hengrui (USA) Ltd., a wholly owned subsidiary of Jiangsu Hengrui Pharmaceuticals Co., Ltd., converted its Series A-2 preferred holdings in Kailera Therapeutics into common stock. On the conversion date, 2,034,133 and 9,477,719 shares of common stock were received from Series A-2 convertible non-voting and Series A-2 convertible preferred stock, respectively, at a stated price of $0.0000 per share. The preferred shares automatically converted into common immediately before Kailera’s initial public offering, leaving no remaining Series A-2 preferred outstanding and establishing a large direct common-stock position, plus 1 share held indirectly by Hengrui (USA) Ltd.
Bain Capital–affiliated entities significantly increased their stake in Kailera Therapeutics, Inc. through BCPE Perseus Investor, LP. On April 20, 2026, BCPE Perseus reported an open-market purchase of 8,398,438 shares of Kailera common stock at $16.00 per share, bringing one reported indirect holding line to 26,255,581 shares.
On the same date, each share of Kailera’s Series B Preferred Stock automatically converted into common stock on a 1:1 basis upon the closing of Kailera’s initial public offering, resulting in 17,857,143 newly issued common shares and reducing the reported Series B Preferred Stock position to zero. All securities are held directly by BCPE Perseus, while Bain Capital Investors, LLC and related Bain Capital funds may be deemed to share voting and dispositive power but disclaim beneficial ownership except for their pecuniary interests.
Kailera Therapeutics director and 10% owner Adam Koppel, through an affiliated fund, reported a large net share increase. On April 20, 2026, an entity associated with him made an open-market purchase of 1,562,500 shares of Common Stock at $16.00 per share, bringing its reported Common Stock holdings to 22,583,268 shares held indirectly.
The filing also shows automatic conversions of 16,875,000 shares of Series A-1 Preferred Stock and 4,145,768 shares of Series B Preferred Stock into Common Stock on a 1:1 basis upon the closing of Kailera’s initial public offering, eliminating those preferred positions. Separately, on April 16, 2026, Dr. Koppel received a grant of stock options for 38,300 shares at an exercise price of $16.00, vesting fully on April 16, 2027.
Kailera Therapeutics, Inc. reported that investment entities affiliated with Bain Capital Life Sciences increased their indirect stake. BCLS Fund IV Investments, L.P. bought 1,562,500 shares of common stock in an open-market purchase at $16.00 per share.
On the same date, BCLS Fund IV Investments, L.P. also acquired additional common stock through automatic 1:1 conversions of Series A-1 and Series B Preferred Stock upon the closing of Kailera’s initial public offering. After these transactions, BCLS Fund IV Investments, L.P. indirectly held 22,583,268 shares of Kailera common stock.
BCPE Perseus Investor, LP, an entity associated with Kailera Therapeutics, Inc. director and 10% owner Andrew T. Kaplan, bought 8,398,438 shares of Kailera Therapeutics common stock at $16.00 per share on April 20, 2026 in an open-market transaction reported as indirect ownership.
On the same date, 17,857,143 shares of Series B Preferred Stock held by BCPE Perseus automatically converted into an equal number of common shares on a 1:1 basis upon the closing of Kailera’s initial public offering. Following these transactions, BCPE Perseus is reported as indirectly holding 26,255,581 common shares, while Kaplan also received a direct grant of stock options for 38,300 shares at a $16.00 exercise price that vest on April 16, 2027. Kaplan disclaims beneficial ownership of BCPE Perseus’ holdings except to the extent of his pecuniary interest.
Kailera Therapeutics Chief People Officer Paula Cloghessy reported two grants of stock options, each covering 60,000 shares of common stock at an exercise price of $16.00 per share, expiring on April 16, 2036.
One option grant vests 25% of the shares on April 16, 2027, then in 36 substantially equal monthly installments, contingent on continued service. The second grant vests, if at all, only if the stock reaches $40 per share during a 30-day average or in a qualifying change in control between October 16, 2026 and April 16, 2030, also requiring continued service.
Kailera Therapeutics, Inc. reported that Chief Legal Officer Scott Akamine received two grants of stock options, each covering 60,000 shares of common stock at an exercise price of $16.00 per share, as compensation awards.
One 60,000-share option vests over time, with 25% vesting on April 16, 2027 and the remainder in 36 monthly installments, subject to continued service. The second 60,000-share option vests only if the company’s stock reaches at least $40 per share during a defined performance period or in a qualifying change in control, also requiring continued service.
Kailera Therapeutics, Inc. director, CEO & President Ronald C. Renaud Jr. was granted stock options linked to the company’s common stock. The Form 4 shows two awards of stock options, each covering 300,000 shares at an exercise price of $16.00 per share, expiring on April 16, 2036.
One option grant vests 25% on April 16, 2027 and then in 36 equal monthly installments, as long as he continues in service. The second grant vests only if the stock reaches $40 per share during a defined performance period or in a qualifying change in control, also requiring continued service through vesting.
Kailera Therapeutics reported that officer Paul D. Burgess received two grants of stock options, each covering 100,000 shares of common stock at an exercise price of $16.00 per share. These are compensation awards, not open‑market purchases.
One option grant vests over time, with 25% vesting on April 16, 2027 and the remainder in 36 equal monthly installments, subject to continued service. The second grant vests only if the company’s stock price reaches $40 during a defined performance period or in a qualifying change in control, with both awards expiring on April 16, 2036.
Kailera Therapeutics, Inc. reported that director John F. Milligan received a grant of stock options covering 38,300 shares of common stock. The options have an exercise price of $16.00 per share and expire on April 16, 2036.
The options vest and become exercisable in full on April 16, 2027, as long as Milligan continues to serve the company through that date. Following this grant, he holds stock options for 38,300 underlying shares directly.
Kailera Therapeutics, Inc. reported that Chief Commercial Officer Jamie Beth Coleman received two stock option awards, each covering 75,000 shares of common stock at an exercise price of $16 per share.
One option vests 25% on April 16, 2027 and then in 36 equal monthly installments, conditioned on continued service. The second option vests only if, during the period from October 16, 2026 to April 16, 2030, the company’s stock trades at or above $40 per share for 30 consecutive trading days or reaches at least $40 per share in a qualifying change in control, also subject to continued service.
Kailera Therapeutics director Martin Mackay received a new stock option grant. On April 16, 2026, he was granted options to acquire 38,300 shares of Common Stock at an exercise price of $16.00 per share.
The options were granted as compensation, not through an open‑market purchase or sale, and are held directly. They vest and become exercisable for 100% of the underlying shares on April 16, 2027, subject to his continued service. Following this grant, he holds 38,300 stock options, which expire on April 16, 2036.
Kailera Therapeutics, Inc. granted Chief Medical Officer Scott M. Wasserman two stock option awards, each covering 100,000 shares of common stock at an exercise price of $16.00 per share and expiring on April 16, 2036.
One option grant vests 25% on April 16, 2027 and then in 36 equal monthly installments, contingent on continued service. The other becomes exercisable only if the company’s stock price reaches at least $40 per share during a defined performance measurement period or in a qualifying change in control, also subject to continued service.
Kailera Therapeutics, Inc. director Christopher Hite received a grant of stock options covering 38,300 shares of common stock. The options have an exercise price of $16.00 per share and expire on April 16, 2036.
The options vest and become exercisable for 100% of the underlying 38,300 shares on April 16, 2027, subject to his continued service through that date. This is a compensation-related award, not an open-market purchase or sale of shares.
Kailera Therapeutics, Inc. director Frank Clyburn received a grant of stock options on April 16, 2026. The award covers 38,300 options to buy common stock at an exercise price of $16.00 per share, all held as direct ownership.
Following this grant, Clyburn holds 38,300 stock options. According to the terms, the options vest and become exercisable for 100% of the underlying shares on April 16, 2027, provided he continues to serve the company through that vesting date. The options are scheduled to expire on April 16, 2036 if not exercised.
Kailera Therapeutics, Inc. Chief Financial Officer Douglas W. Pagan reported two compensatory stock option grants. Each award covers 100,000 shares of common stock at an exercise price of $16.00 per share and expires on April 16, 2036.
One option grant vests 25% on April 16, 2027 and then in 36 substantially equal monthly installments, conditioned on continued service. The second option grant vests, if at all, only if the company’s stock price reaches $40 per share during a defined performance period or in a qualifying change in control, also subject to continued service.